US advisory panel gives nod for emergency use approval of Pfizer

So far 4.5 crore people have been inoculated since the drive was kicked off on January 16 | Representative photo: iStock

An advisory committee formed by the US government has recommended the emergency approval for the Pfizer-BioNTech coronavirus vaccine.

Stating that the vaccine’s potential benefits outweigh its risks, 17 in the panel voted in favour of it, while four voted against the approval, after an eight-hour public hearing on Thursday, the Food and Drug Administrations (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC).

“There is a clear benefit, and all we have on the other side is theoretical risks,” said committee member Paul Offit, a vaccine expert with the Children’s Hospital of Philadelphia.

The vaccines potential benefits outweigh its risks, he said.

“It’s a huge milestone,” said another member Ofer Levy, a paediatric infectious disease expert and head of the precision vaccine programme at Boston Children’s Hospital.

Related news: India’s pharma industry gear up to ‘immunise the world’ against COVID

The drug, however, awaits the formal nod of the FDA. While the FDA is not necessarily mandated to accept the recommendations of the advisory body, it is expected to do so next week as the administration gears to ship and provide millions of doses of coronavirus vaccines to Americans across the country, with priority being given to the vulnerable population.

The Pfizer vaccine has already been approved for the public in the UK and, Canada.

“Today’s approval by the Food and Drug Administration of the Pfizer-BioNTech COVID-19 vaccine is a bright light in a needlessly dark time. We are grateful to the scientists and researchers who developed this vaccine. And, we are grateful to the scientists and public health experts who evaluated the safety and efficacy of this vaccine free from political influence. The integrity of science led us to this point,” President-elect Joe Biden said in a statement.

“The challenge now is to scale up manufacturing and distribution of the vaccine. We are putting together an experienced team to do just that. Before I take office, we need the Trump administration to purchase the doses it has negotiated with Pfizer and Moderna and to work swiftly to scale manufacturing for the US population and the world. And, we will need Congress to fund our distribution efforts,” Biden said.

The President-elect has vowed to distribute 100 million shots in the first 100 days of his administration. According to FDA Commissioner Stephen M Hahn, after the VRBPAC meeting, FDA career staff will take the committees input into account as they continue their review of the Emergency Use Authorisation (EUA) request to determine whether it has met the standards for safety and effectiveness, as well as refine the instructions for use and the informational materials to be provided to those receiving the vaccine. Congressman Fred Upton said the vaccine is essential in the fight to end the COVID-19 pandemic and restore a sense of normalcy.

According to Johns Hopkins University, the deadly virus has infected over 15.5 million people and claimed more than 292,000 lives in the US — both the figures highest in the world. A separate group of independent advisors to the Centres for Disease Control and Prevention — the advisory committee on immunisation practices — are scheduled to take a look at the data after FDA authorises the vaccine.

(With inputs from agencies)